STOK — Stoke Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1623526 ·
Last close
$23.95
Market Cap
$1.55B
52W High
$40.22
52W Low
$20.32
ADV30
911,796
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 9,325,000 | — | -65,429,000 | -61,618,000 | 393,966,000 | 110,004,000 | 48,419,000 |
| Mar 2026 | 6,229,000 | — | -53,418,000 | -50,003,000 | 443,277,000 | 155,659,000 | 48,400,000 |
| Dec 2025 | 1,402,000 | — | -61,439,000 | -57,934,000 | 418,434,000 | 84,220,000 | 65,977,000 |
| Sep 2025 | 10,632,000 | — | -43,091,000 | -38,347,000 | 360,264,000 | 83,394,000 | 52,159,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-177,987,000
Investing CF
$7,745,000
Financing CF
$181,700,000
CapEx
$-2,693,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.77
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-609,336,000
Inventory
—
Receivables
$8,719,000
ST Investments
$182,814,000
EBIT TTM
$-223,377,000
Pretax Income TTM
$-209,180,000
Interest Exp TTM
—
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$27,588,000
EBITDA
$-221,632,992
Free Cash Flow
$-106,202,000
Enterprise Value
$1,583,060,864
Total Cash
$292,817,984
Total Debt
$2,682,000
Shares Out
64,526,242
Trailing EPS
$-3.39
Book Value
$5.54
ROE
-61.1%
ROA
-35.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 184,420,000 | -20,590,000 | -6,885,000 | 418,434,000 | 65,977,000 | 352,457,000 | 45,585,000 |
| Dec 2024 | 36,555,000 | -101,372,000 | -88,981,000 | 271,555,000 | 42,534,000 | 229,021,000 | -86,851,000 |
| Dec 2023 | 8,780,000 | -114,773,000 | -104,699,000 | 228,342,000 | 68,777,000 | 159,565,000 | -81,067,000 |
| Dec 2022 | 12,405,000 | -104,356,000 | -101,067,000 | 256,067,000 | 71,218,000 | 184,849,000 | -31,866,000 |
TTM Snapshot
Revenues TTM
$32,080,000
NetIncome TTM
$-169,767,000
OpCashFlow TTM
—
Assets (Latest)
$443,277,000
Forward EPS
$-3.52
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $22.50 · spot: $24.74 · call volume: 38 · put volume: 282
Expected Move to 2026-11-20:
±$5.20
(21.02%) —
implied range
$19.54 –
$29.94
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QURE | uniQure N.V. | $1.56B | $22.54 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.56B | $54.75 | — |
| KRSA | Korsana Biosciences, Inc. | $1.53B | $33.51 | — |
| SNDX | Syndax Pharmaceuticals Inc | $1.51B | $16.90 | — |
| INVA | Innoviva, Inc. | $1.51B | $20.87 | — |
News headlines (Yahoo Finance, 1h cache)
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Ann
2026-10-06 12:00 · Yahoo
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-09-16 20:01 · Yahoo
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
2026-09-03 23:30 · Yahoo
Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts
2026-08-18 00:01 · Yahoo
Stoke Therapeutics (STOK) Q2 2026 Earnings Call Transcript
2026-08-11 01:58 · Yahoo
What Is Stoke Therapeutics (STOK) Signaling With A 2 Million Share Shelf Filing?
2026-08-07 06:14 · Yahoo
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-08-05 12:00 · Yahoo
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
2026-08-03 21:10 · Yahoo
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating
2026-08-21 09:53 · Yahoo
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
2026-10-05 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.